The following question refers to Sections 3.3 and 3.4 of the 2021 ESC CV Prevention Guidelines.
The question is asked by CardioNerds Academy Intern student Dr. Adriana Mares, answered first by Brigham & Women’s medicine resident & Director of CardioNerds Internship Dr. Gurleen Kaur, and then by expert faculty Dr. Allison Bailey.
Dr. Bailey is an advanced h ... Show More
Jul 2022
REBOOT #191 Lipids and Cardiovascular Risk Reduction with Erin Michos MD
Lipids Update! Get up close and personal with ASCVD prevention and lipid management guidelines, including changes in the 2018 update, with our discussion with Dr. Erin Michos @erinmichos, preventive cardiologist and associate professor of medicine at the Johns Hopkins University ... Show More
1h 15m
Jul 2022
USPSTF Recommendation: Behavioral Counseling Interventions to Promote Healthy Behaviors for CVD Prevention
Interview with Lori Pbert, PhD, USPSTF member and coauthor of Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recomme ... Show More
19m 55s
May 2021
Covid-19: Vaccination in pregnancy, myocardial infarction, and respiratory conditions
Kieran Walsh, clinical director at BMJ, asks editors from BMJ Learning and BMJ Best Practice to summarise the latest clinical guidance related to covid-19. Emma Scott, section editor, updates us on vaccination for pregnant and breastfeeding women. And Abigail Davis, GP and sectio ... Show More
9m 29s
Sep 2025
AI, Polygenic Risk Scores, and Antithrombotic Therapy | JACC This Week
In this episode, Editor-in-Chief Harlan Krumholz explores the evolving landscape of cardiovascular medicine, beginning with a call for responsible stewardship of artificial intelligence. Highlights include a major registry study on percutaneous aspiration for right-sided endocard ... Show More
9m 54s
Mar 2023
Eagle’s Eye View: What is the Association of Cardiac Damage on Health Status Both Before and After AVR?
In this week’s View, Dr. Eagle discusses Lp(a) as a main driver for the risk of ASCVD, MI, and aortic valve stenosis independent of CRP. This article is timely as we continue to attempt to lower the risks with ongoing trials currently working on relevant therapeutic options for l ... Show More
8m 26s